Vascular endothelial growth factor [VEGF-634G/C] polymorphism and retinopathy of prematurity a meta-analysis

Vascular endothelial growth factor polymorphism [VEGF-634G/C, rs 2010963] has been considered a risk factor for the development of retinopathy of prematurity [ROP]. However, the results remain controversial. Therefore, the aim of the present meta-analysis was to determine the association between VEGF-634G/C polymorphism and ROP risk. Published literature from PubMed and other databases were retrieved. All studies evaluating the association between VEGF-634G/C polymorphism and ROP risk were included. Pooled odds ratio [OR] and 95% confidence interval [Cl] were calculated using random or fixed effects model. A total of six case-control studies including 355 cases and 471 controls were included. By pooling all the studies, we found that VEGF-634G/C polymorphism was not associated with ROP risk at co-dominant and allele levels and no association was also found in dominant and recessive models. While stratifying on ethnicity level no association was observed in Caucasian and Asian population. This meta-analysis suggests that VEGF-634G/C polymorphism may not be associated with ROP risk, the association between single VEGF-634G/C polymorphism and ROP risk awaits further investigation

Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion

To evaluate the anatomical and functional efficacy of combination therapy of intravitreal ranibizumab with laser or intravitreal bevacizumab with laser treatment compared to only laser treatment for macular edema due to branch retinal vein occlusion [BRVO]. Thirty eyes of 30 patients with BRVO of at least 6 weeks duration were randomized into three groups- Group 1 received a single dose of intravitreal Ranibizumab followed by grid laser treatment. Group 2 received a single dose of intravitreal Bevacizumab followed by grid laser treatment, and Group 3 received grid laser alone. Outcomes at 6 months follow-up were reported. Data were collected on best corrected visual acuity [BCVA], central foveal thickness [CFT], and gain in lines of Snellen acuity. At 6 month follow up, the difference in the mean BCVA and CFT between the three treatment groups was not statistically significant [P> 0.05, all comparisons]. Six eyes [60%] in Group 1, four eyes [40%] in Group 2 and two eyes [20%] in Group 3 had a statistically significant gain of >/=3 lines of Snellen acuity [P< 0.05]. Both ranibizumab and bevacizumab combined with laser photocoagulation, resulted in better outcomes than grid laser treatment